High-grade Glioma
High-grade Glioma Market

High-Grade Gliomas (HGG) are tumors of the central nervous system (CNS). They are solid tumors from transformed cells called astrocytes of the brain and/or the spinal cord. 

The symptoms primarily result from the pressure that the tumor first exerts on the adjacent brain tissue and later on, in an advanced stage, on the entire brain (or spinal cord). Also, edema of adjacent normal brain (or spinal cord) tissue caused by the tumor plays a significant role in developing clinical symptoms. Additionally, depending on the tumor’s localization and the patient’s age, various other symptoms can happen, such as rapidly rising head-circumference (macrocephalus), developmental delay, headaches, backaches, nausea and puking in the morning, dizziness, gait disturbances, impaired vision, lack of focus, drowsiness, sleep disturbances, dysregulated appetite, paralyzes, and/or seizures.

High-Grade Gliomas Epidemiological Segmentation 

The Epidemiological Segmentation of High-Grade Gliomas in 7MM from 2017 to 2030 is segmented as:- 

  • Incident Population of CNS Brain Tumour
  • Incident Population of High-Grade Glioma
  • Gender-specific Incidence of High-Grade Glioma
  • Diagnosed and Treatable Cases of High-Grade Glioma
  • Mutation-specific incidence (specifically H3K27M mutation) of High-Grade Glioma
  • Type-specific incidence of HGG {Diffuse Intrinsic Pontine Glioma (DIPG), Anaplastic Astrocytomas and Glioblastoma Multiforme (GBM)} 

High-Grade Gliomas Epidemiology 

  • HGGs account for around 15-20% of CNS tumors in children and adolescents.
  • The incidence rate of HGG is 5-10 new diagnoses per 1.000.000 children per year.
  • HGG is more common in men than in women. 

High-Grade Gliomas Emerging Drugs

The emerging drugs of the High-Grade Gliomas market are 

  • BMX-001
  • ONC201
  • Nivolumab (Opdivo)
  • ABI-009
  • DSP-7888
  • Ribociclib
  • Paxalisib (GDC-0084)

And many others.  


High-Grade Gliomas Key Players

The key players in the High-Grade Gliomas market are

  • BioMimetix
  • Oncoceutics
  • Bristol-Myers Squibb
  • Istari Oncology
  • Aadi Bioscience
  • Sumitomo Dainippon Pharma
  • Novartis Pharmaceuticals
  • Kazia Therapeutics 

And many others.